Download the Complete Report Here By Rayk Riechmann After tracking the meteoric rise of Digital Asset Treasury (DAT) companies in our June 2025 report, HODL On Tight – The Rise of Public Market Crypto Treasuries, the strategy has boomed with countless companies across industries and geographies embracing it. To help investors spot potential winners, we’ve published an industry update focusing on the most critical indicators to monitor. DAT companies provide regulated, liquid, and transparent access to blo ...

Core Insights - Processa Pharmaceuticals, Inc. has secured a strategic investment and is exploring corporate cryptocurrency treasury strategies to enhance financial flexibility and long-term value creation [1][2][4] Group 1: Strategic Financial Initiatives - The company believes that engaging with emerging financial technologies, including select cryptocurrencies, may diversify its capital base and enhance financial flexibility [2][3] - Processa is committed to compliance with regulatory standards while recognizing the potential of blockchain-based assets to fund clinical development programs, thereby reducing dilution for existing shareholders [3][4] Group 2: Corporate Development and Partnerships - The company is focused on long-term value creation, transparency, and responsible stewardship of investor capital, as stated by CEO George Ng [4] - Processa has engaged LifeSci Capital, LLC as an advisor for implementing its cryptocurrency treasury strategy [4] Group 3: Company Overview - Processa Pharmaceuticals is a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies aimed at improving safety and efficacy for cancer patients [5] - The company's strategy involves modifying existing FDA-approved oncology therapies to enhance their effectiveness while maintaining their cancer-killing mechanisms [5]